GSK plc (GSK) Stock Price, Fundamentals & Analysis
Price
18.51 GBP
-1.39%
Last trade: Sep 25, 2026, 04:35 PM GMT+1
Updated: Sep 27, 2026, 10:44 AM GMT+1
Price history
Over the past year GSK traded between 14.86 GBP and 22.68 GBP, closing at 18.51 GBP on Sep 25, 2026.
Key statistics
| Market cap | 74.14B GBP |
|---|---|
| P/E ratio (TTM) | 15.7 |
| Forward P/E | 9.7 |
| EPS (TTM) | 1.18 GBP |
| Dividend yield | 3.67% |
| Annual dividend | 0.68 GBP |
| Ex-dividend date | Aug 13, 2026 |
| Payout ratio | 57% |
| 52-week range | 14.95 – 22.82 |
| 52-week change | 23.6% |
| Beta | 0.29 |
| Price / book | 420.3 |
| Revenue (TTM) | 33.2B GBP |
| Revenue growth (YoY) | 5.3% |
| Gross margin | 73.5% |
| Operating margin | 30.9% |
| Profit margin | 14.5% |
| Return on equity | 33.4% |
| Debt / equity | 106.5 |
| Volume | 4,920,309 |
| Average volume | 7,009,669 |
| Next earnings | Oct 28, 2026 |
| Exchange | LSE |
Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 66,841
- Headquarters
- London, United Kingdom
- Website
- gsk.com
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
Overview
What GSK does
GSK plc (GSK) is a Healthcare sector company in the Drug Manufacturers - General industry, listed on the London Stock Exchange. The company researches, develops, and manufactures vaccines, specialty medicines, and general medicines in the United Kingdom, the United States, and internationally. Its specialty medicines cover areas such as oncology, respiratory and immunology, inflammation, and inhaled treatments for conditions including HIV, lupus, ovarian cancer, and endometrial cancer. GSK also offers vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, and Human Papilloma Virus, among others, alongside general medicines for asthma, COPD, and allergic rhinitis.
Key numbers explained
- 18.51 GBP is the current share price, the amount you would pay for one share on the London Stock Exchange.
- The trailing P/E ratio of 15.7 shows how much investors pay per pound of the company's last 12 months of earnings.
- The forward P/E ratio of 9.7 uses expected future earnings, often making it easier to compare with peers like AstraZeneca (AZN).
- 3.67% is the dividend yield, the annual dividend income as a percentage of the share price.
- The ex-dividend date is 13 aug. 2026, the cutoff date to own the stock and receive the next dividend payment.
- 57% of earnings are paid out as dividends, showing the portion of profit returned to shareholders.
- 0.29 is the beta, a measure of volatility relative to the market; a value below 1 suggests lower sensitivity to market swings.
- The 52-week price range of 14,95 – 22,82 shows the lowest and highest traded prices over the past year.
What to watch
- Revenue growth of 5.3% year over year and a profit margin of 14.5% show how the company converts sales into earnings.
- The operating margin of 30.9% and return on equity of 33.4% indicate how efficiently GSK uses its resources to generate profit.
- A debt-to-equity ratio of 106.5% means debt and equity are roughly balanced, a level investors monitor for financial risk.
- The price-to-book ratio of 420.3 compares the share price to the company's book value per share, a metric often used in asset-heavy industries.
- GSK's next earnings report is scheduled for 28 oct. 2026, a common date investors watch for updates on performance and outlook.
Latest news & filings
No recent headlines.
Frequently asked questions
Does GSK pay a dividend?
Yes, GSK pays a dividend with a yield of 3.67%, and 57% of earnings are distributed to shareholders.
What is the GSK P/E ratio?
The trailing P/E ratio is 15.7, while the forward P/E ratio based on expected earnings is 9.7.
Where can I buy GSK?
GSK trades on the London Stock Exchange under the symbol GSK.
What does GSK do?
GSK researches, develops, and manufactures vaccines, specialty medicines, and general medicines for conditions including oncology, respiratory diseases, and infections.
How volatile is GSK compared to the market?
GSK has a beta of 0.29, suggesting it is less volatile than the overall market.
Related
More on GSK
Track GSK in your portfolio
Hold GSK at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free